Two other clinical trials, SURVEYOR-1 and -2, compared short courses of treatment (eight weeks) with a combination of ABT-493 and ABT-530 in people suffering from HCV who had or did not have cirrhosis. The studies were open-label and analyzed data based on HCV genotype. Success rates were above 97% among those with genotypes 1 and 2 and 100% among those with genotype 3 -- even in patients who suffered from cirrhosis. This was also true without the addition of ribavirin. The medication was well tolerated.
While the results look promising, these studies were fairly small, including fewer than 100 participants. The medications do, however, meet many of the requirements of an ideal drug: 100% effectiveness, short course of treatment, active against multiple genotypes (including genotype 3), no ribavirin or interferon, excellent tolerability. Their cost remains an open question, though.
Credit: Bobboz for iStock via Thinkstock.